Cancer Breakthrough, But Stock Drops?!

Verastem just dropped some seriously promising cancer trial results—over 50% response in pancreatic cancer patients! But get this: their stock still fell 19%. Retail investors are suddenly bullish, and analysts are all in with ‘Buy’ ratings and a $15.75 price target (that’s 150% upside). The twist? Some think the China partnership is spooking the market. Wild how good news can still send stocks tumbling! #CancerResearch #StockMarket #Biotech #Health